Program
Piroxicam
Also written as “Piroxicam ( BAYl1902)”, “Piroxicam plus Counterirritant (brand name Counterpain® PXM).” and “Felden (piroxicam) Tablets”.
Its studies are mostly in Ankle Injuries · Pain · Dysmenorrhea, led by 4 companies.
Drug pagePiroxicam: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Bayerits history only | 10 open or running | phase 2since Mar 21, 2011 | Mar 21, 2011 | none ahead |
| Nanoform Finland | 10 open or running | phase 1since Mar 28, 2021 | Mar 28, 2021 | none ahead |
| Pfizerits history only | 10 open or running | phase 4since Mar 28, 2008 | Mar 28, 2008 | none ahead |
| Taisho Pharmaceuticalits history only | 10 open or running | phase 3since Feb 19, 2026 | Feb 19, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Nanoform Finland only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 28, 2021First study: phase 1 study in PainFirst studyNCT05104931 · 12 enrolled · United Kingdom
TargetBeta
“Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Flurbiprofenrule | GlaxoSmithKline | phase 3 | 12 |
Studies
The one study Nanoform Finland leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05104931Pain · United Kingdom | 1 | Completed | Feb 1, 2021 | 12 |
How it is read
Names in the registry
- “Piroxicam ( BAYl1902)”, 3 entries
- “Piroxicam plus Counterirritant (brand name Counterpain® PXM).”, 1 entry
- “Felden (piroxicam) Tablets”, 1 entry
- “Brexidol (piroxicam) Tablets”, 1 entry
- “piroxicam”, 1 entry
Conditions, from the studies’ own filings
- Ankle Injuries, 1 study
- Pain, 1 study
- Dysmenorrhea, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.